Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00743652 · ClinicalTrials.gov registry record · Phase 3

Study Evaluating the Impact of the 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Alaskan Native Children.

A Phase 3 study of Pneumococcal Disease and 13-valent Pneumococcal Vaccine, sponsored by Pfizer.

Completed
Registry status
Phase 3
Development phase
373
Enrollment target
20
Study locations

NCT00743652 is a Phase 3 study of Pneumococcal Disease and 13-valent Pneumococcal Vaccine that has completed, run by Pfizer. The registered enrollment target is 373 participants, below the 463-participant average among 3 other Pneumococcal Disease trials with a reported enrollment target (19% lower). The trial reports 20 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00743652, a Phase 3 study of Pneumococcal Disease and 13-valent Pneumococcal Vaccine, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 3
Development phase
373 participants
Enrollment target
20
Study locations

Study Summary

This study is to evaluate the safety, immunogenicity and impact of 13-valent Pneumococcal conjugate vaccine in Alaskan Native Children.

Conditions Studied

Pneumococcal Disease 13-valent Pneumococcal Vaccine

Interventions

  • BIOLOGICAL 13-valent Pneumococcal Conjugate Vaccine

Study Locations (20)

Alaska

  • Pfizer Investigational Site - Akiak
  • Pfizer Investigational Site - Bethel
  • Pfizer Investigational Site - Chefornak
  • Pfizer Investigational Site - Chevak
  • Pfizer Investigational Site - Eek
  • Pfizer Investigational Site - Emmonak
  • Pfizer Investigational Site - Hooper Bay
  • Pfizer Investigational Site - Kalskag
  • Pfizer Investigational Site - Kasigluk
  • Pfizer Investigational Site - Kongiganak
  • Pfizer Investigational Site - Kotlik
  • Pfizer Investigational Site - Kwethluk
  • Pfizer Investigational Site - Kwigillingok
  • Pfizer Investigational Site - Mountain Village
  • Pfizer Investigational Site - Napaskiak
  • Pfizer Investigational Site - Newtok
  • Pfizer Investigational Site - Nunapitchuk
  • Pfizer Investigational Site - Russian Mission
  • Pfizer Investigational Site - Scammon Bay
  • Pfizer Investigational Site - Toksook Bay

Trial Details

FieldValue
Enrollment Target 373 participants
Start Date 2009-01
Est. Completion 2010-09
Phase Phase 3

Sponsor

Pfizer

1,845 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00743652

The ClinicalTrials.gov registry entry for NCT00743652 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 373 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 463-participant average among 3 other Pneumococcal Disease trials with a reported enrollment target (19% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Pneumococcal Disease appearing as the primary indexed condition, and to 1 intervention - of which 13-valent Pneumococcal Conjugate Vaccine is the first listed.

NCT00743652 reports 20 study locations spanning 1 distinct geographic area - top geographies include Alaska.

Frequently Asked Questions

What is clinical trial NCT00743652 about?

NCT00743652 is a clinical study titled "Study Evaluating the Impact of the 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Alaskan Native Children.". This study is to evaluate the safety, immunogenicity and impact of 13-valent Pneumococcal conjugate vaccine in Alaskan Native Children.

What is the current status of trial NCT00743652?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 373 participants. The study started on 2009-01. Estimated completion is 2010-09.

What conditions does trial NCT00743652 study?

This clinical trial studies the following conditions: Pneumococcal Disease, 13-valent Pneumococcal Vaccine.

What interventions are being tested in trial NCT00743652?

The interventions under investigation include: 13-valent Pneumococcal Conjugate Vaccine (BIOLOGICAL).

Who is sponsoring clinical trial NCT00743652?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00743652 being conducted?

This trial has 20 study locations across Alaska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Pneumococcal Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Pneumococcal Disease

All registered trials for this condition

13-valent Pneumococcal Vaccine

All registered trials for this condition

Alaska

All trials with a study site in Alaska

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.